*NEWS: Med-Device Startup Announces Beneficial Study Findings

A med-device startup announced the findings of a recent study that described its tech as a non-invasive optical imaging method for rapidly assessing compromised circulation in tissue in lower extremities.

Modulim, formerly known as Modulated Imaging, announced the news in an April 23 press release. See related story on its recent $7 million raise here.

The study examined the ability of “SFDI,” spatial frequency domain imaging. SFDI is an advanced imaging technique co-invented by David Cuccia, who serves as Modulim’s CEO and CTO, and his former colleagues at UCI’s Beckman Laser Institute.

SFDI is an FDA-cleared, non-invasive, tissue oxygen saturation technology that combines structured illumination with multiple wavelengths of light (visible and near-infrared). This enables deeper and layer-specific assessment of tissue oxygenation and hemoglobin.

The results showed that SFDI revealed a certain, unique profile of a diabetic foot. These findings suggested that, in patients with diabetes, oxygen was not appropriately extracted by the tissue, due to capillary dysfunction.

The study was completed in collaboration with Modulim and researchers from University of Arizona’s Icahn School of Medicine and USC’s Keck School of Medicine.

David Cuccia, CEO and CTO, Modulim

Cuccia and Amaan Mazhar, Modulim’s VP of R&D, are internationally-recognized experts in the field of medical photonics. They’re also co-authors of the study, which was funded by one of the institutes at the National Institutes of Health.

About The Author

Deirdre Newman is a long-time journalist, who's covered OC startups for a few years.

You don't have permission to register